Showing results (121-130 of 174) with videos related to

Sort By:
Pageof 18
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid TumorsManuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
Clinical and Translational Science|May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed HepatotoxicityMarije B Overdijk, Kristin Strumane, Ruth Plummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through ProteogenomicsMaria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, et al.
Molecular Oncology|April 25, 2023
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre networkNúria Mulet Margalef, Carmen Castillo, Miguel Mosteiro, et al.
Nature Medicine|June 5, 2020
Author Correction: Caring for patients with cancer in the COVID-19 eraJoris van de Haar, Louisa R Hoes, Charlotte E Coles, et al.
Nature Medicine|May 15, 2020
Caring for patients with cancer in the COVID-19 eraJoris van de Haar, Louisa R Hoes, Charlotte E Coles, et al.
Cell Reports. Medicine|February 11, 2025
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancersStephane Champiat, Elena Garralda, Vladimir Galvao, et al.
Journal for Immunotherapy of Cancer|July 20, 2026
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignanciesRandy F Sweis, Ignacio Melero, Diwakar Davar, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2026
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphomaElena Garralda, Patrick Schöffski, Arjun Oberoi, et al.
Pageof 18